Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bardoxolone methyl in rare chronic kidney diseases (PHOENIX)
NCT03366337Phase 2Completed
- Sponsor
- Biogen
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
A Phase 2 trial of bardoxolone methyl in IgA nephropathy (IgAN), Type 1 Diabetic Nephropathy (T1DN), focal segmental glomerulosclerosis (FSGS), autosomal dominant polycystic kidney disease (ADPKD), sponsored by Biogen. Started Dec 2017; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
IgA nephropathy (IgAN)Type 1 Diabetic Nephropathy (T1DN)focal segmental glomerulosclerosis (FSGS)autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03366337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366337.